Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Glaxosmithkline Plc
Amendment - Director/PDMR Shareholding
Business
Apr 16 2024
4 min read

Amendment - Director/PDMR Shareholding

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:

-     A typographical correction to the share price for the transaction shown in the table below.

All other details to the original announcement remain unchanged.

The amended table is shown below.

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.3860

19






d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price


e)

Date of the transaction

2024-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)